Homologues and isomers of noladin ether, a putative novel endocannabinoid: Interaction with rat cannabinoid CB1 receptors

Bioorganic and Medicinal Chemistry Letters

Volumn 13, Issue 1, 2003, Pages 43-46

  Appendino, Giovanni ^a   Ligresti, Alessia ^b   Minassi, Alberto ^a   Daddario, Nives ^a   Bisogno, Tiziana ^b   Di Marzo, Vincenzo ^b  

^a UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^b CNR   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

2 ARACHIDONYLGLYCERYL ETHER; CANNABINOID; CANNABINOID 1 RECEPTOR; FATTY ACID DERIVATIVE; RADIOLIGAND; RIMONABANT; TRITIUM; UNCLASSIFIED DRUG; ACYLGLYCEROL; CANNABINOID RECEPTOR; DRUG RECEPTOR; ENDOCANNABINOID; NOLADIN ETHER; UNSATURATED FATTY ACID;

ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BRAIN MEMBRANE; BRAIN TISSUE; CHEMICAL STRUCTURE; CONTROLLED STUDY; DRUG RECEPTOR BINDING; DRUG SCREENING; DRUG SYNTHESIS; ISOMER; LIGAND BINDING; NONHUMAN; RAT; RECEPTOR BINDING; ANIMAL; BRAIN; CELL MEMBRANE; CHEMISTRY; METABOLISM; PROTEIN BINDING; RADIOASSAY; STEREOISOMERISM; STRUCTURE ACTIVITY RELATION; SYNTHESIS; ULTRASTRUCTURE;

ANIMALS; BRAIN; CELL MEMBRANE; ENDOCANNABINOIDS; FATTY ACIDS, UNSATURATED; GLYCERIDES; PROTEIN BINDING; RADIOLIGAND ASSAY; RATS; RECEPTORS, CANNABINOID; RECEPTORS, DRUG; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 1842864772     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(02)00839-9     Document Type: Article

References (17)

1. Hanus L., Abu-Lafi S., Fride E., Breuer A., Vogel Z., Shalev D.E., Kustanovich I., Mechoulam R. Proc. Natl. Acad. Sci. U.S.A. 98:2001;3662.
2. Pertwee R.G. Pharmacol. Ther. 74:1997;129.
3. (a) Devane, W. A.; Hanus, L.; Breuer, A.; Pertwee, R. G.; Stevenson, L. A.; Griffin, G.; Gibson, D.; Mandelbaum, A.; Etinger, A.; Mechoulam, R. Science, 1992, 258, 1946.
4. (b) Mechoulam R., Ben-Shabat S., Hanus L., Ligumsky M., Kaminski N.E., Schatz A.R., Gopher A., Almog S., Martin B.R., Compton D.R., Pertwee R.G., Griffin G., Bayewitch M., Barg J., Vogel Z. Biochem. Pharmacol. 50:1995;83.
5. (c) Sugiura T., Kondo S., Sukagawa A., Nakane S., Shinoda A., Itoh K., Yamashita A., Waku K. Biochem. Biophys. Res. Commun. 215:1995;89.
6. (a) Di Marzo V., Bisogno T., De Petrocellis L., Melck D., Martin B.R. Curr. Med. Chem. 6:1999;721.
7. (b) Palmer S.L., Khanolkar A.D., Makriyannis A. Curr. Pharm. Des. 6:2000;1381.
8. (c) Reggio P.H. Prostaglandins Leukot. Essent. Fatty Acids. 66:2002;143.
9. 3 and extraction with EtOAc. After removal of the solvent, the residue was purified by CC (13 g silica gel, petroleum ether-EtOAc 9:1 as eluant) to give 161 mg (50%) 7l as a colourless oil.
10. (a) Melck D., Bisogno T., De Petrocellis L., Chuang H., Julius D., Bifulco M., Di Marzo V. Biochem. Biophys. Res. Commun. 262:1999;275.
11. (b) Abood M.E., Ditto K.E., Noel M.A., Showalter V.M., Tao Q. Biochem. Pharmacol. 53:1997;207.
12. Pertwee R.G. Curr. Med. Chem. 6:1999;635.
13. 3H]HU-243 was 0.70±0.16 μM (n=3) with rat brain membranes (Di Marzo, V.; Bisogno, T.; Ligresti, A. unpublished observations).
14. Nagan N., Zoeller R.A. Prog. Lipid. Res. 40:2001;199.
15. (a) Felder C.C., Joyce K.E., Briley E.M., Mansouri J., Mackie K., Blond O., Lai Y., Ma A.L., Mitchell R.L. Mol. Pharmacol. 48:1995;443.
16. (b) Sugiura T., Kodaka T., Natane S., Miyashita T., Kondo S., Suhara Y., Takayama H., Waku K., Seki C., Baba N., Ishima Y. J. Biol. Chem. 274:1999;2794
17. (c) Sheskin T., Hanus L., Slager J., Vogel Z., Mechoulam R. J. Med. Chem. 40:1997;659.